In Section A, contributors will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. More members will probably be enrolled with the discovered monotherapy dosign program. In Segment B, participants will obtain oral ruxolitinib and ABBV-744 are going to be offered as "incorporate-on" therapy. In https://abbv-744-in-acute-myeloid24578.blogdiloz.com/31166297/the-best-side-of-abbv-744-clinical-trial-phase-2-data